Common Contracts
173 similar Placement Agency Agreement contracts by Aclarion, Inc., Calidi Biotherapeutics, Inc., Revelation Biosciences, Inc., others
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • April 19th, 2024 • Cyclacel Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • April 18th, 2024 • Wisa Technologies, Inc. • Semiconductors & related devices • New York
This letter agreement (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and WiSA Technologies, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), that Maxim shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, for the proposed placement to certain purchasers (the “Purchasers”) of up to an aggregate of 225,834 units (each a “Unit” and collectively, the “Units”), with each Unit consisting of (A) one share (each a “Share” and collectively, the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and (B) one common stock purchase warrant (the “Warrant”) to purchase one share of Common Stock (the “Warrant Shares”). The Units and the securities included therein (i.e., the Shares, the Warrants and the Warrant Shares) are referred to herein as the “Securities.” The documents executed and delivered by the Company and the Purchasers
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • April 15th, 2024 • Aptevo Therapeutics Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENT April [*], 2024Placement Agency Agreement • April 8th, 2024 • Calidi Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • April 4th, 2024 • Sintx Technologies, Inc. • Surgical & medical instruments & apparatus • New York
PLACEMENT AGENCY AGREEMENT April [*], 2024Placement Agency Agreement • April 1st, 2024 • Calidi Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • March 27th, 2024 • Wisa Technologies, Inc. • Semiconductors & related devices • New York
This letter agreement (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and WiSA Technologies, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), that Maxim shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, for the proposed placement to certain purchasers (the “Purchasers”) of up to an aggregate of 76,676,478 units (each a “Unit” and collectively, the “Units”), with each Unit consisting of (i) 62,675,000 common units (each a “Common Unit” and collectively, the “Common Units”), with each Common Unit consisting of (A) one share (each a “Share” and collectively, the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and (B) one common stock purchase warrant (the “Warrant”) to purchase one share of Common Stock (the “Warrant Shares”), and (ii) 14,001,478 pre-funded units (each a “Pre-Funded Unit” and collectively, the “Pre
PLACEMENT AGENCY AGREEMENT March 25, 2024Placement Agency Agreement • March 26th, 2024 • Sintx Technologies, Inc. • Surgical & medical instruments & apparatus • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • March 25th, 2024 • Danimer Scientific, Inc. • Plastic materials, synth resins & nonvulcan elastomers • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • March 13th, 2024 • Nuwellis, Inc. • Electromedical & electrotherapeutic apparatus • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • March 8th, 2024 • bioAffinity Technologies, Inc. • Services-commercial physical & biological research • New York
Subject to the terms and conditions herein (this “Agreement”), bioAffinity Technologies Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $2,500,000 of registered and unregistered securities of the Company, including, but not limited to, an aggregate of 1,600,000 shares of the Company’s common stock (the “Shares”) par value $0.007 per share (the “Common Stock”), and unregistered common stock purchase warrants to purchase up to an aggregate of 1,600,000 shares of Common Stock (the “Warrants” and the Common Stock underlying the Warrants, the “Warrant Shares”, and the Shares, the Warrants and the Warrant Shares, the “Securities”) directly to various investors (each, an “Investor” and, collectively, the “Investors”) through WallachBeth Capital, LLC as placement agent (the “Placement Agent”). The documents executed and delivered by the Company and the Investors in connection with the Offering (as defined below), including, without limitation, a securi
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • March 5th, 2024 • First Wave BioPharma, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • February 23rd, 2024 • Aclarion, Inc. • Services-medical laboratories • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • February 16th, 2024 • Wisa Technologies, Inc. • Semiconductors & related devices • New York
This letter agreement (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and WiSA Technologies, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), that Maxim shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, for the proposed placement to certain purchasers (the “Purchasers”) of an aggregate of (i) 23,734,000 common units (each a “Common Unit” and collectively, the “Common Units”), with each Common Unit consisting of (A) one share (each a “Share” and collectively, the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and (B) one common stock purchase warrant (the “Warrant”) to purchase one share of Common Stock (the “Warrant Shares”), which are not exercisable until after the Stockholder Approval Date (as defined in the Warrant) and expiring on the fifth (5th) anniversary of the date on which Stockholder Approval is rec
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • February 16th, 2024 • Ohmyhome LTD • Real estate agents & managers (for others) • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • February 12th, 2024 • Tenax Therapeutics, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENT February 1, 2024Placement Agency Agreement • February 8th, 2024 • Revelation Biosciences, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENT February [*], 2024Placement Agency Agreement • February 7th, 2024 • Calidi Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • February 6th, 2024 • Ohmyhome LTD • Real estate agents & managers (for others) • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • February 6th, 2024 • Aclarion, Inc. • Services-medical laboratories • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • February 2nd, 2024 • Sintx Technologies, Inc. • Surgical & medical instruments & apparatus • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • February 1st, 2024 • Tenax Therapeutics, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENT January 31, 2024Placement Agency Agreement • February 1st, 2024 • Applied Dna Sciences Inc • Services-testing laboratories • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • January 30th, 2024 • SeaStar Medical Holding Corp • Surgical & medical instruments & apparatus • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • January 29th, 2024 • Revelation Biosciences, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • January 29th, 2024 • Panbela Therapeutics, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • January 23rd, 2024 • Bio-Path Holdings Inc • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • January 4th, 2024 • Panbela Therapeutics, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • January 3rd, 2024 • Fortress Biotech, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 26th, 2023 • Cyclacel Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 22nd, 2023 • Revelation Biosciences, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 18th, 2023 • First Wave BioPharma, Inc. • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 13th, 2023 • Beachbody Company, Inc. • Retail-nonstore retailers • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 11th, 2023 • Aclarion, Inc. • Services-medical laboratories • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 8th, 2023 • U Power LTD • Motor vehicle parts & accessories • New York
